ClinicalTrials.gg
CompletedNCT00704262Updated Mar 7, 2025Results posted

Effect of Calcipotriol Plus Hydrocortisone Ointment on the Adrenal Hormone Balance and Calcium Metabolism in Patients With Psoriasis Vulgaris on the Face and Skin Folds

A Phase 2 interventional study of Calcipotriol plus hydrocortisone (LEO 80190) in Psoriasis Vulgaris, sponsored by LEO Pharma. Completed at 11 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-07.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies testing calcipotriene in Psoriasis — 2 open to participants now, 2 under way, none of them phase 3. calcipotriene · Psoriasis.

Enrollment
35th of 47
33 · median 200
Started
2008
with 4 others
Phase 2
9 of 47
none open now
Registered
16th of 47
by date
Lead sponsor
22 of 47
LEO Pharma

Among the 47 studies testing calcipotriene in Psoriasis, this one is the 35th largest by enrollment, is one of 5 that started in 2008, is one of 9 in phase 2, and was the 16th registered.

Psoriasis

2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.

Browse Psoriasis studies →

Open to participants now

2 of the 47 studies testing calcipotriene in Psoriasis are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About calcipotriene

calcipotriene: first FDA approval 1993 (DOVONEX). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies testing calcipotriene in Psoriasis, or all of them as a file.
02

Study summary

There are few therapies suitable for the treatment of psoriasis on the face and skin folds. As these areas are sensitive, irritation and other adverse reactions are more common than elsewhere on the body. The purpose of the study is to monitor the effect of once daily treatment for up to 8 weeks of an ointment containing calcipotriol 25 mcg/g plus hydrocortisone 10 mg/g on the hypothalamic-pituitary-adrenal axis and on the calcium metabolism in patients with psoriasis vulgaris on the face and on the intertriginous areas

03

Conditions studied

  • Psoriasis Vulgaris

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of psoriasis vulgaris involving the face and the intertriginous areas
  • Clinical diagnosis of psoriasis vulgaris on the trunk and/or limbs or earlier diagnosed with psoriasis vulgaris on the trunk and/or limbs
  • An extent of psoriatic involvement on the face of at least 5 cm2 and the sum of all facial and intertriginous lesions at least 30 cm2
  • Treatment areas (face and intertriginous) amenable to topical treatment with a maximum of 100g ointment per week
  • Disease severity of the face and intertriginous areas graded as moderate, severe or very severe according to the investigator´s global assessment of disease severity
  • Patients with a normal HPA axis function: serum cortisol concentration above 5 mcg/dl before adrenocorticotropic hormone (ACTH: tetracosactid/cosyntropin) injection and serum cortisol concentration above 18 mcg/dl 30 min after ACTH (tetracosactid/cosyntropin) injection
  • Albumin corrected serum calcium within reference range
  • Females of have to use a highly effective method of during the study (hormonal contraceptives on oestrogen basis are not allowed)

Exclusion criteria

Exclusion Criteria:

  • A history of active allergy, asthma, allergic skin rash, or sensitivity to any medication (including ACTH/tetracosactid/cosyntropin) or to any component of the formulations being tested
  • Systemic treatment with all other therapies than biologicals, with a potential effect on psoriasis vulgaris (eg vitamin D analogues, retinoids)within 2 weeks prior to Visit 1. Stable treatment with methotrexate or fumaric acid is allowed
  • Systemic treatment with within 12 weeks prior to Visit 1
  • Systemic use of biological treatments, whether marketed or not, directed against or with a potential effect on psoriasis vulgaris (eg. alefacept, efalizumab, etanercept, infliximab, adalimumab) within 12 weeks prior to Visit 1
  • Psoralen plus ultraviolet light A (PUVA) therapy or Grenz ray therapy within 4 weeks prior to Visit 1
  • Ultraviolet B (UVB) therapy within 2 weeks prior to Visit 1
  • Topical treatment with World Health Organization (WHO) group 2, 3 or 4 corticosteroids within 4 weeks prior to Visit 1
  • Topical treatment with WHO group 1 corticosteroids within 2 weeks prior to Visit 1
  • Any topical treatment of the face and intertriginous areas (except for emollients) within 2 weeks prior to Visit 1
  • Oestrogen therapy or any other medication known to affect cortisol levels or HPA-axis integrity within 4 weeks prior to Visit 1
  • Enzymatic inductors, systemic or topical cytochrome P450 inhibitors, hypoglycaemic sulfonamides or antidepressive medication within 4 weeks prior to Visit 1
  • Current diagnosis of erythrodermic, exfoliative, guttate or pustular psoriasis
  • Patients with any of the following conditions present on the treatment area: viral (e.g., herpes or varicella) lesions of the skin, fungal and bacterial skin infections, parasitic infections, skin manifestations in relation to syphilis or tuberculosis, rosacea, perioral dermatitis, acne vulgaris, atrophic skin, striae atrophicae, fragility of skin veins, ichthyosis, acne rosacea, ulcers and wounds
  • Other inflammatory skin diseases (e.g., seborrhoeic dermatitis, contact dermatitis and cutaneous mycosis) that may confound the evaluation of psoriasis vulgaris on the face or on the intertriginous areas
  • Planned exposure to sun, Ultraviolet A (UVA) or UVB during the study that may affect the psoriasis vulgaris
  • Clinical signs or symptoms of Cushing´s disease or Addison's disease
  • Known or suspected severe renal insufficiency or severe hepatic disorders
  • Known or suspected disorders of calcium metabolism associated with hypercalcaemia
  • Known or suspected endocrine disorder that may affect the results of the ACTH challenge test
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (actual)

Study arms

  • Experimental
    Calcipotriol plus hydrocortisone (LEO 80190)

    Drug: Calcipotriol plus hydrocortisone (LEO 80190)

Interventions

06

What researchers measure

Primary outcomes

  1. The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 and 60 Minutes

    The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.

    Time frame: At Week 4 (Day 28) and Week 8 (Day 56)

  2. Change in Albumin Corrected Serum Calcium

    Baseline was defined as the last assessment performed before study medication application. The end of treatment data was defined as the last value recorded during the treatment phase (i.e. Week 4, 6, or 8).

    Time frame: From baseline to Week 4, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8)

Secondary outcomes

  1. The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 Minutes

    The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.

    Time frame: At Week 4 and Week 8

  2. The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 60 Minutes

    The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.

    Time frame: At Week 4 and Week 8

  3. Serum Cortisol Concentration After 30 Minutes

    The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin.

    Time frame: At Week 4 and Week 8

  4. Serum Cortisol Concentration After 60 Minutes

    The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin.

    Time frame: At Week 4 and Week 8

  5. Change in Albumin Corrected Serum Calcium

    Baseline was defined as the last assessment performed before study medication application.

    Time frame: From baseline to Week 2 and Week 6

  6. Albumin Corrected Serum Calcium

    The end of treatment data was defined as the last value recorded during the treatment phase (i.e. Week 4, 6, or 8).

    Time frame: At Week 2, Week 4, Week 6 and Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)

  7. Albumin Corrected Serum Calcium Values Above the Upper Limit of the Reference Range

    The table summarizes the shifts in albumin corrected serum calcium versus the normal range. The end of treatment data was defined as the last value recorded for the parameter during the treatment phase of the study (i.e. Week 4, 6, or 8). The normal reference range for the albumin corrected serum calcium was defined as 2.1-2.64 mmol/L (8.4-10.6 mg/L). The value below this level was considered 'low', while the value above this range was considered 'high'.

    Time frame: At Week 2, Week 4, Week 6 and Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)

  8. Participants With "Controlled Disease" ("Clear" or "Almost Clear") According to the Investigator's Global Assessment of Disease Severity (IGA) of the Face

    Controlled disease was defined as the following (P=Plaque thickening, S=Scaling, E=Erythema) Clear (Plaque thickening=no elevation/thickening of normal skin, S=no evidence of scaling, E= none/hyperpigmentation/residual red coloration) or Almost clear (P=none/possible thickening but difficult to ascertain whether there is a slight elevation above normal skin level, S=none/residual surface dryness and scaling, E=light pink coloration) (last value recorded i.e. Week 4, 6, or 8)

    Time frame: At Week 4, Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)

  9. Participants With "Controlled Disease" ("Clear" or "Almost Clear") According to the IGA of the Intertriginous Areas

    Controlled disease was defined as the following: Clear (Infiltration = no elevation or thickening of normal skin, Erythema = normal skin colour or hyperpigmentation) or Almost clear (Infiltration = no elevation or thickening of normal skin, Erythema = faint pink colour) The end of treatment data was defined as the last value recorded for the efficacy measure.

    Time frame: At Week 4, Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)

  10. Overall Disease Severity of the Face According to the IGA

    6-category scale based on plaque thickening (P), Scaling (S), Erythema (E). Clear (P=no elevation/thickening of normal skin, S=no evidence of scaling, E=none/hyperpigmentation/residual red coloration) Almost clear (P=none/possible thickening but difficult to ascertain whether there is a slight elevation above normal skin level, S=none/residual surface dryness and scaling, E=light pink coloration) Mild (P=slight but definite elevation, S=fine scales partially/mostly covering lesions, E=light red coloration) Moderate (P=moderate elevation with rounded or sloped edges, S=most lesions at least partially covered, E=definite red coloration) Severe (P =marked elevation typically with hard or sharp edges, S=non-tenacious scale predominates, covering most or all of the lesions, E=very bright red coloration) Very severe (P=very marked elevation typically with hard or sharp edges, S=thick tenacious scale covers most or all of the lesions, E=extreme red coloration, deep red coloration)

    Time frame: At baseline, Week 2, Week 4, Week 6, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8)

  11. Overall Disease Severity of Intertriginous Areas According to the IGA

    The assessment of the disease severity of the intertriginous areas was made using the 6-category scale; clear, almost clear, mild, moderate, severe, very severe. Clear (Infiltration = no elevation or thickening of normal skin, Erythema = normal skin colour or hyperpigmentation) Almost clear (Infiltration = no elevation or thickening of normal skin, Erythema = faint pink colour) Mild (Infiltration = slight, subtle thickening or infiltration, only marginally increased from normal skin, Erythema = light pink colour) Moderate (Infiltration = palpable thickening or infiltration without elevation, Erythema = definite pink colour) Severe (Infiltration = palpable thickening or infiltration with elevation, Erythema = very bright red coloration) Very severe (Infiltration = marked thickening or infiltration with rounded or sloped edges, Erythema = bright deep red coloration)

    Time frame: At baseline, Week 2, Week 4, Week 6, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8)

07

Results

Posted Oct 20, 2020

Participant flow

The treatment phase was divided into two 4-week treatment periods during which the overall treatment duration had to be 28 days or 56 days. The participant was to leave the study if they were clear according to the investigator's global assessment of disease severity (IGA) of the face and of the intertriginous areas at Visit 3 (Day 28).

Participant flow — Overall Study
MilestoneCalcipotriol Plus Hydrocortisone (LEO 80190)
Started33
Completed31
Not completed2

Outcome measures

PrimaryThe Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 and 60 Minutes

The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.

Time frame:
At Week 4 (Day 28) and Week 8 (Day 56)
Reported as:
Count of participants · Participants
The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 and 60 Minutes
ParticipantsCalcipotriol Plus Hydrocortisone (LEO 80190)
>18 mcg/dL29
≤18 mcg/dL1
PrimaryChange in Albumin Corrected Serum Calcium

Baseline was defined as the last assessment performed before study medication application. The end of treatment data was defined as the last value recorded during the treatment phase (i.e. Week 4, 6, or 8).

Time frame:
From baseline to Week 4, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Reported as:
Mean · mmol/L
Change in Albumin Corrected Serum Calcium
mmol/LCalcipotriol Plus Hydrocortisone (LEO 80190)
Baseline2.215 (2.188 to 2.243)
Week 4 (Day 28)0.002 (-0.026 to 0.029)
Week 8 (Day 56)-0.045 (-0.083 to -0.007)
End of Treatment (last value recorded)-0.033 (-0.066 to 0.000)
SecondaryThe Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 Minutes

The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.

Time frame:
At Week 4 and Week 8
Reported as:
Count of participants · Participants
The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 30 Minutes
ParticipantsCalcipotriol Plus Hydrocortisone (LEO 80190)
>18 mcg/dL29
≤18 mcg/dL1
SecondaryThe Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 60 Minutes

The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin. ≤18 mcg/dL was considered low.

Time frame:
At Week 4 and Week 8
Reported as:
Count of participants · Participants
The Adrenal Response to the ACTH Challenge Test Defined as the Serum Cortisol Concentration Obtained After 60 Minutes
ParticipantsCalcipotriol Plus Hydrocortisone (LEO 80190)
>18 mcg/dL30
≤18 mcg/dL0
SecondarySerum Cortisol Concentration After 30 Minutes

The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin.

Time frame:
At Week 4 and Week 8
Reported as:
Mean · mcg/dL
Serum Cortisol Concentration After 30 Minutes
mcg/dLCalcipotriol Plus Hydrocortisone (LEO 80190)
Week 4 (Day 28)25.29 ± 4.35
Week 8 (Day 56)25.93 ± 4.73
SecondarySerum Cortisol Concentration After 60 Minutes

The adrenal function was assessed by a rapid standard dose ACTH (tetracosactid/cosyntropin) challenge test. The ACTH challenge test consisted of a baseline blood (Day -7 to Day -3) sample taken at 8 a.m. (± 30 minutes). Following the baseline blood sample, an intravenous bolus injection of 250 mcg Synacthen®/Cortrosyn® was given at Time 0 (T = 0). Serum cortisol concentrations at 30 and 60 minutes after administration were taken and reflected the stimulation induced by tetracosactid/cosyntropin.

Time frame:
At Week 4 and Week 8
Reported as:
Mean · mcg/dL
Serum Cortisol Concentration After 60 Minutes
mcg/dLCalcipotriol Plus Hydrocortisone (LEO 80190)
Week 4 (Day 28)28.81 ± 3.48
Week 8 (Day 56)28.82 ± 5.30
SecondaryChange in Albumin Corrected Serum Calcium

Baseline was defined as the last assessment performed before study medication application.

Time frame:
From baseline to Week 2 and Week 6
Reported as:
Mean · mmol/L
Change in Albumin Corrected Serum Calcium
mmol/LCalcipotriol Plus Hydrocortisone (LEO 80190)
Baseline2.215 ± 0.077
Week 2 (Day 14)0.018 ± 0.095
Week 6 (Day 42)-0.013 ± 0.083
SecondaryAlbumin Corrected Serum Calcium

The end of treatment data was defined as the last value recorded during the treatment phase (i.e. Week 4, 6, or 8).

Time frame:
At Week 2, Week 4, Week 6 and Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Reported as:
Mean · mmol/L
Albumin Corrected Serum Calcium
mmol/LCalcipotriol Plus Hydrocortisone (LEO 80190)
Week 2 (Day 14)2.233 ± 0.079
Week 4 (Day 28)2.217 ± 0.074
Week 6 (Day 42)2.208 ± 0.096
Week 8 (Day 56)2.179 ± 0.085
End of Treatment (last value recorded)2.182 ± 0.081
SecondaryAlbumin Corrected Serum Calcium Values Above the Upper Limit of the Reference Range

The table summarizes the shifts in albumin corrected serum calcium versus the normal range. The end of treatment data was defined as the last value recorded for the parameter during the treatment phase of the study (i.e. Week 4, 6, or 8). The normal reference range for the albumin corrected serum calcium was defined as 2.1-2.64 mmol/L (8.4-10.6 mg/L). The value below this level was considered 'low', while the value above this range was considered 'high'.

Time frame:
At Week 2, Week 4, Week 6 and Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Reported as:
Count of participants · Participants
Albumin Corrected Serum Calcium Values Above the Upper Limit of the Reference Range
ParticipantsCalcipotriol Plus Hydrocortisone (LEO 80190)
Week 2 (Day 14) — Low2
Week 2 (Day 14) — Normal30
Week 2 (Day 14) — High0
Week 4 (Day 28) — Low3
Week 4 (Day 28) — Normal30
Week 4 (Day 28) — High0
Week 6 (Day 42) — Low2
Week 6 (Day 42) — Normal26
Week 6 (Day 42) — High0
Week 8 (Day 56) — Low6
Week 8 (Day 56) — Normal21
Week 8 (Day 56) — High0
End of Treatment (last value recorded) — Low6
End of Treatment (last value recorded) — Normal27
End of Treatment (last value recorded) — High0
SecondaryParticipants With "Controlled Disease" ("Clear" or "Almost Clear") According to the Investigator's Global Assessment of Disease Severity (IGA) of the Face

Controlled disease was defined as the following (P=Plaque thickening, S=Scaling, E=Erythema) Clear (Plaque thickening=no elevation/thickening of normal skin, S=no evidence of scaling, E= none/hyperpigmentation/residual red coloration) or Almost clear (P=none/possible thickening but difficult to ascertain whether there is a slight elevation above normal skin level, S=none/residual surface dryness and scaling, E=light pink coloration) (last value recorded i.e. Week 4, 6, or 8)

Time frame:
At Week 4, Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Reported as:
Count of participants · Participants
Participants With "Controlled Disease" ("Clear" or "Almost Clear") According to the Investigator's Global Assessment of Disease Severity (IGA) of the Face
ParticipantsCalcipotriol Plus Hydrocortisone (LEO 80190)
Week 4 (Day 28) — Controlled21
Week 4 (Day 28) — Non-controlled12
Week 8 (Day 56) — Controlled19
Week 8 (Day 56) — Non-controlled9
End of Treatment (last value recorded) — Controlled23
End of Treatment (last value recorded) — Non-controlled10
SecondaryParticipants With "Controlled Disease" ("Clear" or "Almost Clear") According to the IGA of the Intertriginous Areas

Controlled disease was defined as the following: Clear (Infiltration = no elevation or thickening of normal skin, Erythema = normal skin colour or hyperpigmentation) or Almost clear (Infiltration = no elevation or thickening of normal skin, Erythema = faint pink colour) The end of treatment data was defined as the last value recorded for the efficacy measure.

Time frame:
At Week 4, Week 8 and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Reported as:
Count of participants · Participants
Participants With "Controlled Disease" ("Clear" or "Almost Clear") According to the IGA of the Intertriginous Areas
ParticipantsCalcipotriol Plus Hydrocortisone (LEO 80190)
Week 4 (Day 28) — Controlled20
Week 4 (Day 28) — Non-controlled13
Week 8 (Day 56) — Controlled19
Week 8 (Day 56) — Non-controlled9
End of Treatment (last value recorded) — Controlled23
End of Treatment (last value recorded) — Non-controlled10
SecondaryOverall Disease Severity of the Face According to the IGA

6-category scale based on plaque thickening (P), Scaling (S), Erythema (E). Clear (P=no elevation/thickening of normal skin, S=no evidence of scaling, E=none/hyperpigmentation/residual red coloration) Almost clear (P=none/possible thickening but difficult to ascertain whether there is a slight elevation above normal skin level, S=none/residual surface dryness and scaling, E=light pink coloration) Mild (P=slight but definite elevation, S=fine scales partially/mostly covering lesions, E=light red coloration) Moderate (P=moderate elevation with rounded or sloped edges, S=most lesions at least partially covered, E=definite red coloration) Severe (P =marked elevation typically with hard or sharp edges, S=non-tenacious scale predominates, covering most or all of the lesions, E=very bright red coloration) Very severe (P=very marked elevation typically with hard or sharp edges, S=thick tenacious scale covers most or all of the lesions, E=extreme red coloration, deep red coloration)

Time frame:
At baseline, Week 2, Week 4, Week 6, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Reported as:
Count of participants · Participants
Overall Disease Severity of the Face According to the IGA
ParticipantsCalcipotriol Plus Hydrocortisone (LEO 80190)
Baseline — Clear0
Baseline — Almost clear0
Baseline — Mild0
Baseline — Moderate27
Baseline — Severe6
Baseline — Very severe0
Week 2 (Day 14) — Clear0
Week 2 (Day 14) — Almost clear12
Week 2 (Day 14) — Mild15
Week 2 (Day 14) — Moderate5
Week 2 (Day 14) — Severe1
Week 2 (Day 14) — Very severe0
Week 4 (Day 28) — Clear5
Week 4 (Day 28) — Almost clear16
Week 4 (Day 28) — Mild9
Week 4 (Day 28) — Moderate2
Week 4 (Day 28) — Severe1
Week 4 (Day 28) — Very severe0
Week 6 (Day 42) — Clear5
Week 6 (Day 42) — Almost clear15
Week 6 (Day 42) — Mild7
Week 6 (Day 42) — Moderate1
Week 6 (Day 42) — Severe0
Week 6 (Day 42) — Very severe0
Week 8 (Day 56) — Clear5
Week 8 (Day 56) — Almost clear14
Week 8 (Day 56) — Mild6
Week 8 (Day 56) — Moderate3
Week 8 (Day 56) — Severe0
Week 8 (Day 56) — Very severe0
End of Treatment (last value recorded) — Clear9
End of Treatment (last value recorded) — Almost clear14
End of Treatment (last value recorded) — Mild6
End of Treatment (last value recorded) — Moderate3
End of Treatment (last value recorded) — Severe1
End of Treatment (last value recorded) — Very severe0
SecondaryOverall Disease Severity of Intertriginous Areas According to the IGA

The assessment of the disease severity of the intertriginous areas was made using the 6-category scale; clear, almost clear, mild, moderate, severe, very severe. Clear (Infiltration = no elevation or thickening of normal skin, Erythema = normal skin colour or hyperpigmentation) Almost clear (Infiltration = no elevation or thickening of normal skin, Erythema = faint pink colour) Mild (Infiltration = slight, subtle thickening or infiltration, only marginally increased from normal skin, Erythema = light pink colour) Moderate (Infiltration = palpable thickening or infiltration without elevation, Erythema = definite pink colour) Severe (Infiltration = palpable thickening or infiltration with elevation, Erythema = very bright red coloration) Very severe (Infiltration = marked thickening or infiltration with rounded or sloped edges, Erythema = bright deep red coloration)

Time frame:
At baseline, Week 2, Week 4, Week 6, Week 8, and end of treatment (last value recorded i.e. Week 4, 6, or 8)
Reported as:
Count of participants · Participants
Overall Disease Severity of Intertriginous Areas According to the IGA
ParticipantsCalcipotriol Plus Hydrocortisone (LEO 80190)
Baseline — Clear0
Baseline — Almost clear0
Baseline — Mild0
Baseline — Moderate19
Baseline — Severe12
Baseline — Very severe2
Week 2 (Day 14) — Clear0
Week 2 (Day 14) — Almost clear7
Week 2 (Day 14) — Mild16
Week 2 (Day 14) — Moderate9
Week 2 (Day 14) — Severe1
Week 2 (Day 14) — Very severe0
Week 4 (Day 28) — Clear5
Week 4 (Day 28) — Almost clear15
Week 4 (Day 28) — Mild10
Week 4 (Day 28) — Moderate2
Week 4 (Day 28) — Severe1
Week 4 (Day 28) — Very severe0
Week 6 (Day 42) — Clear4
Week 6 (Day 42) — Almost clear17
Week 6 (Day 42) — Mild5
Week 6 (Day 42) — Moderate2
Week 6 (Day 42) — Severe0
Week 6 (Day 42) — Very severe0
Week 8 (Day 56) — Clear7
Week 8 (Day 56) — Almost clear12
Week 8 (Day 56) — Mild7
Week 8 (Day 56) — Moderate2
Week 8 (Day 56) — Severe0
Week 8 (Day 56) — Very severe0
End of Treatment (last value recorded) — Clear10
End of Treatment (last value recorded) — Almost clear13
End of Treatment (last value recorded) — Mild7
End of Treatment (last value recorded) — Moderate2
End of Treatment (last value recorded) — Severe1
End of Treatment (last value recorded) — Very severe0

Adverse events

Collected over From baseline visit (Day -7 to -3) to Follow-up 1 (end of treatment +14 ± 2) and Follow-up 2 (end of treatment +28 ± 2).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Calcipotriol Plus Hydrocortisone (LEO 80190)0/33 (0%)0/33 (0%)15/33 (45.5%)
Most frequent other events
Showing 10 of 24
Most frequent other events
EventCalcipotriol Plus Hydrocortisone (LEO 80190)
HeadacheNervous system disorders4/33
NasopharyngitisInfections and infestations3/33
NauseaGastrointestinal disorders2/33
Back painMusculoskeletal and connective tissue disorders2/33
LymphadenopathyBlood and lymphatic system disorders1/33
Ear disorderEar and labyrinth disorders1/33
Irritable bowel syndromeGastrointestinal disorders1/33
Application site burningGeneral disorders1/33
Application site pruritusGeneral disorders1/33
BronchitisInfections and infestations1/33

Baseline characteristics

Age, Continuous
Age, Continuous(years)Calcipotriol Plus Hydrocortisone (LEO 80190)
Mean47.4 ± 15.9
Sex: Female, Male
Sex: Female, Male(Participants)Calcipotriol Plus Hydrocortisone (LEO 80190)
Female14
Male19
Region of Enrollment
Region of Enrollment(participants)Calcipotriol Plus Hydrocortisone (LEO 80190)
Canada8
United States7
United Kingdom11
Germany7
08

Study locations

11 sites
  • Burke Pharmaceuticals
    Hot Springs, Arkansas 71913, United States
  • Dermatology Research of Arkansas
    Little Rock, Arkansas 72205, United States
  • Ameriderm Research
    Ormond Beach, Florida 32174, United States
  • Somerset Skin Center
    Troy, Michigan 48084, United States
  • Psoriasis Treatment Center of Central NJ
    East Windsor, New Jersey 08520, United States
  • Virginia Clinical Research, Inc.
    Norfolk, Virginia 23507, United States
  • The Guenther Dermatology Research Centre
    London, Ontario N6A3H7, Canada
  • Institute of Clinical Pharmacology Parexel International Gmbh
    Berlin, 12351, Germany
  • LCG Bioscience
    Bourn, Cambridge CB3 7TR, United Kingdom
  • ICON Development Solutions
    Manchester, M15 6SH, United Kingdom
  • The Dermatology Centre, Hope Hospital
    Manchester, M6 8HD, United Kingdom
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of May 2008, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2020, 10 years 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2008
First posted
Jun 24, 2008
Start
May 2008
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Oct 20, 2020
Last update
Mar 7, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00704262
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Jun 24, 2008
Start date
May 2008
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Oct 20, 2020
Last update
Mar 7, 2025

Study contacts

Rainard Fuhr, MD, PhD
principal investigator · Institute of Pharmacology Parexel International GmbH, Spandauer Damm 130, Haus 31, 14050 Berlin, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Calcipotriene · Hydrocortisone

Start the discussion